Lab Report

TEST REPORT
Lab. Id : P1508068 Hosp. UHID : Reg. Date : 05-Sep-2023 / 13:59 PM

Name : MR. ROYDEN D SOUZA Collection : 05-Sep-2023 / 00:00 AM
Age/Gender : 29Y / Male Received : 05-Sep-2023 / 14:32 PM
Collected At : FPEC BEJAI Report : 05-Sep-2023 / 15:00 PM
Referral Dr : SELF Report Status : Preliminary Print :
Bed
:
Biochemistry
Investigation Observed Value Unit Biological Ref. Interval Specimen
KIDNEY FUNCTION TEST

UREA 25.00 mg/dl 12.8 - 42.8 Serum
CREATININE 0.90 mg/dl 0.8 - 1.44 Serum

Method:Enzymatic
URIC ACID 6.9 mg/dl 3.4 - 7.0 Serum

Method:Uricase
TOTAL PROTEIN 7.6 g/dL 6.4 - 8.3 Serum

Method:Biuret
ALBUMIN 4.6 g/dL 3.5 - 5.2 Serum

Method:BCG
GLOBULIN 3.0 g/dL 2.3-3.5 Serum

Method:Calculated
A/G RATIO 1.53 1-2 Serum

Method:Calculated
ALKALINE PHOSPHATASE 55.0 U/L 40 - 130 Serum

Method:IFCC-PNPP With AMP Buffer
CALCIUM 9.1 mg/dl 8.6 - 10.2 Serum

Method:N-BAPTA
PHOSPHORUS 3.4 mg/dl 2.5-4.5 Serum
SODIUM 143.0 mmol/l 137-145 Serum

Method:ISE
POTASSIUM 4.2 mmol/l 3.5-5.3 Serum

Method:ISE
CHLORIDE 105.0 mmol/l 98-107 Serum

Method:Indirect ISE
Comments:
Kidneys play several vital roles like filtration/removal of toxic wastes and metabolites from the blood, RBC production, Vitamin D metabolism and
regulation of blood pressure. It is recommended in following conditions:
1. To evaluate kidney functioning in normal individuals as screening test
2. To aid in diagnosis of kidney related disorders (Acute and chronic renal failure, pyelonephritis, End Stage Renal Disease)
3. To screen those who may be at risk of developing kidney disorders (Diabetes, Hypertension, Cardiovascular diseases)
4. To monitor someone on treatment for kidney related disorders
5. To monitor effects of nephrotoxic drugs (given for other conditions) on kidneys (Vancomycin, methotrexate, some antivirals etc)
Results of the panel are usually considered together, rather than separately. Individual test result can be abnormal due to causes other than
kidney disease, but taken together with risks and signs and symptoms, they may give an indication of whether kidney disease is present.
Verified By: 185848
Aster Clinical Lab Mangalore,Plot no 9, Building no 3E-16-1370/2, R sy no.97/2A, T Sy no 158/2A,kadri

village,Mangalore city kankanady, dakshina kannada
Page 1 Of 12
TEST REPORT
Name : MR. ROYDEN D SOUZA Collection :
Age/Gender : 29Y / Male Received :
Collected At : FPEC BEJAI Report :
Referral Dr : SELF Report Status : Print :
Bed
:
Dr. Aravind P
MD Pathology
--- End Of Report ---

Important Instructions:
Test results released pertain to specimen submitted.
All results are dependent upon the quality of specimen received in the laboratory.
Lab investigation is only a tool to faciilitate in concluding a diagnosis , and should be clinically correlated by the referring physician.
Certain tests may require further testing, at an additional cost for derivation of excact value. kindly submit request with in 2 days, post reporting.
Sample repeats are accepted on request of Referring Physician with in sample stability period.
Test results may show inter-laboratory variation.
Results are for informational purposes , and not intended to replace the care of medical practitionar, and does not recommend self-diagnosis
and/or self-medication.
Aster clinical Lab LLP does not make any warranties expressed or implied with respect to information herein.
Test results are not valid for medico legal purposes.
The courts/forum at Cochin/Bangolore shall have exclusive Jurisdiction in all disputes/claims concerning the request and/or result of test(s).
Contact customer care 9680396803 for all queries related to test results
Patient/Client is advised to contact the laboratory immediately, for any possible remedial action, If test result is alarming or unexpected

Page 2 Of 12
TEST REPORT
Bed
:
Haematology
COMPLETE BLOOD COUNT

RBC Parameters
Haemoglobin 16.1 gm/dl 12.0-15.0 K2EDTA
WB
RBC Count 5.50 mil/cmm 3.8-4.8 K2EDTA

Method:Elect. Impedance WB
PCV 47.9 % 36.0-46.0 K2EDTA

WB
MCV 87.2 fl 76.0-96.0 K2EDTA

WB
MCH 29.3 pg 27.0-32.0 K2EDTA

Method:Calculated WB
MCHC 33.6 g/dL 30.0-35.0 K2EDTA

RDW - CV 13.4 % 11 - 15 K2EDTA

WBC Parameters
Total WBC Count 8800 K/uL 4000-11000 K2EDTA
Method:Elect. Impedance WB
WBC Differential
Neutrophils 52.6 % 40-70 K2EDTA
Lymphocytes 34.9 % 20-50 K2EDTA
Monocytes 9.9 % 04-08 K2EDTA
Eosinophils 1.7 % 00-06 K2EDTA
Basophils 0.9 % 00-01 K2EDTA
Absolute Counts
Absolute Neutrophils 4628.8 /cmm 1500-8000 K2EDTA

Method:Measured WB
Absolute Lymphocytes 3071.2 /cmm 1000-4500 K2EDTA

Method:Measured WB

Page 3 Of 12
TEST REPORT
Bed
:
Absolute Monocytes 871.2 /cmm 0-800 K2EDTA

Absolute Eosinophils 149.6 /cmm 0-600 K2EDTA

Method:Measured WB
Absolute Basophils 79.2 /cmm 0-200 K2EDTA

Method:Measured WB
Platelet Parameters
Platelet Count 375000 /cmm 150000-400000 K2EDTA
Method:Electrical Impedance/Flowcytometry WB
MPV 9.4 fl 8.0-11.0 K2EDTA
PDW 13.8 % 11.0-18.0 K2EDTA
Comments:
A complete blood count (CBC) is a blood test which measures several cellular components of blood and is used to evaluate overall
health and detect a wide range of disorders.
It is used to determine one¶s general health status; to screen for, diagnose, or monitor a variety of diseases and conditions that affect
blood cells, such as anemia, infection, inflammation, bleeding disorder or cancer.
A decrease in hemoglobin levels/ RBC count lower than the normal reference range for the given age can signify anemia. Further
investigation with iron studies, vitamin B12 and folic acid levels will help in determining the cause and assist in further treatment. Red
cell indices help in classification of anaemia and give a clue to their etiology. An increase in haemoglobin level may signify
polycythemia, dehydration and is often seen in smokers.
White blood cell (WBC) counts and their differential counts (DC) are used to diagnose infections(bacterial/viral), allergies, inflammatory
conditions and leukemias.
Platelets help in clotting of blood, any substantial decrease may increase the risk of bleeding
Note
The differential leucocyte counts are additionally being reported as absolute numbers of each cell in per unit volume of blood as per the
recommendation of International council for Standardization in Hematology.
Verified By: 185848

Dr. Aravind P
MD Pathology

Page 4 Of 12
TEST REPORT
Bed
:


Page 5 Of 12
TEST REPORT
Bed
:
Biochemistry
GLUCOSE, FASTING (F) 111.0 mg/dl Non-Diabetic: < 100 Fluoride

Method:Hexokinase Prediabetes :100-125 Plasma (F)
Diabetic: >/= 126
Remarks: Sample was not collected in fasting state.
Comments:
Glucose is a simple sugar(monosaccharide) obtained by breakdown of carbohydrates. It is the main source of energy in the body. This test
measures glucose levels in the blood after 8-12 hrs of fasting.
Clinical uses:
1. Diagnosis and monitoring of Diabetes(hyperglycemia)
2. Diagnosis and monitoring of Hypoglycemia
3. Diagnosis of some endocrinal disorders
High levels are seen in:

1. Diabetes ±Type 1 and 2
2. Gestational Diabetes
3. Stress, surgery
4. Endocrinal disorders ±Hyperthyroidism, Hypercortisolism
5. Pancreatic disorders ±Pancreatitis, Glucagonoma
6. Drugs such as steroids, Hydrocortisone
Low levels are seen in:

1. Insulinoma
2. Overdose of Anti diabetic drugs & Insulin
3. Starvation
4. Endocrinal disorders ±Hypothyroidism, Hypopituitarism, Addison¶s disease
5. Chronic kidney and liver disorders
Verified By: 185848

Dr. Aravind P
MD Pathology

Page 6 Of 12
TEST REPORT
Bed
:


Page 7 Of 12
TEST REPORT
Bed
:
Clinical Pathology
Investigation Result Unit Biological Ref. Interval Specimen
URINE ROUTINE EXAMINATION

PHYSICAL EXAMINATION
Color Yellowish Pale Yellow Spot urine
Method:Manual
pH-Urine 6.5 4.5 - 8.0 Spot urine

Method:Methyl Red and Bromothymol blue
Specific Gravity Urine 1.010 1.016-1.022 Spot urine

Method:Refractometry
Transparency Clear Clear Spot urine

Method:Manual
Volume (ml) 15 ml Spot urine

Method:Manual
CHEMICAL EXAMINATION
Proteins Negative Negative Spot urine
Method:Tetrabromophenol blue
Glucose Negative Negative Spot urine

Method:Emzyme (GOD POD)
Ketones Absent Absent Spot urine

Method:Legals Test
Blood Absent Absent Spot urine

Method:Peroxidase
Bilirubin Absent Absent Spot urine

Method:Diazonium Salt
Urobilinogen Normal Normal Spot urine

Method:Diazonium Salt
Nitrite Absent Absent Spot urine

Method:Diazo
MICROSCOPIC EXAMINATION
Pus cells 0-1 /hpf 0-5 Spot urine
RBC Nil
Epithelial Cells 0-1 - - Spot urine
Method:Microscopy
Casts Absent Absent Spot urine

Method:Microscopy
Crystals Absent Absent Spot urine

Amorphous debris Absent Absent Spot urine
Bacteria Not seen 0-50 /hpf Spot urine
Yeast Cells Absent

Page 8 Of 12
TEST REPORT
Bed
:
Bile Pigments Absent Spot urine

Method:Fouchets
Bile Salts Absent Spot urine

Method:Hays sulphur test
leukocytes Absent Spot urine

Method:Chemical Indicator
Verified By: 185848

Dr. Aravind P
MD Pathology


Page 9 Of 12
TEST REPORT
Bed
:
Biochemistry
LIPID PROFILE
TOTAL CHOLESTEROL 160.0 mg/dl Desirable: <200 Borderline-high: Serum
Method:CHOD-POD 200-239 High: >/=240
TRIGLYCERIDES 231.0 mg/dl Normal: <150 Serum
Method:GOD-POD Borderline-high: 150 - 199
High: 200 - 499
Very high:>/=500
HDL CHOLESTEROL 33.0 mg/dl Desirable: >60 Serum

Method:Elimination/Catalase Borderline: 40 - 60
Low (High risk): <40
Non HDL CHOLESTEROL 127 mg/dl 50-130 Serum
Method:Calculated
LDL CHOLESTEROL 80.8 mg/dl Optimal: <100 Near Optimal: 100 - Serum
Method:Elimination/Catalase 129 Borderline High: 130 - 159
High: 160 - 189 Very High: >/= 190
VLDL 46.2 mg/dl 5 - 30 Serum
Method:Calculated
TOTAL CHOLESTEROL/HDLC 4.85 0 - 4.5 Serum

RATIO
Method:Calculated
LDLC/HDLC RATIO 2.45 0 - 3.5 Serum

Method:Calculated
VLDL- Cholesterol 46.2
Comments:
Lipid profile is a panel of blood tests that serves as an initial screening tool for abnormalities in lipids, such as cholesterol and triglycerides. The
lipid panel is used as part of a cardiac risk assessment to help determine your risk of heart disease and to help make decisions about what
treatment may be best if you have borderline, intermediate or high risk.
The results of the lipid panel are considered along with other known risk factors of heart disease to develop a plan of treatment and follow up.
Depending on the results and other risk factors, treatment options may involve lifestyle changes such as diet and exercise or medications that
lower lipid levels, typically statins.
Additionally a lipid panel may be used to monitor whether treatment has been effective in lowering cholesterol levels.
NLA 2014-15 guidelines:

1. Non±HDL-C (calculated as total C ±HDLC) represents the sum of cholesterol carried by all potentially atherogenic, apo B-containing
lipoprotein particles, including LDL, IDL, Lp (a), VLDL (including VLDL remnants), and chylomicron particles and remnants.
2. An elevated level of cholesterol carried by circulating apolipoprotein (apo) B±containing lipoproteins (non±HDL-C and LDL-C, termed
atherogenic cholesterol) is a root cause of atherosclerosis/ASCVD. HDL-C is responsible for lowering peripheral tissue cholesterol(reverse
transport), inturn reducing risk of ASCVD.
3. Apolipoprotein B, hsCRP, Lp(a) and LP-PLA2 testing should be considered in patients with moderate risk for ASCVD.
4. In all adults (>20 years of age), a fasting or nonfasting lipid profile should be obtained at least every 5 years. At a minimum, this should
include total cholesterol and HDL-C, which allows calculation of non-HDL-C (total-C ±HDL-C). If fasting (generally 9±12 hours), the LDL-C level
may be calculated, provided that the triglyceride concentration is <400 mg/dL.
5. Apo B is considered an optional, secondary target for treatment. Epidemiologic studies have generally shown that both apo B and non±HDL-C
are better predictors of ASCVD risk than LDL-C. Apo B and non±HDL-C share the advantage that neither requires fasting sample for accurate

Page 10 Of 12
TEST REPORT
Bed
:
assessment.
6. Elevated triglyceride level is not a target of therapy per se, except when very high (>500 mg/dL). When triglycerides are between 200 and
499 mg/dL, the targets of therapy are non±HDL-C and LDL-C. When triglycerides are very high (>500 mg/dL, and especially if >1000 mg/dL),
reduction to <500 mg/dL to prevent pancreatitis becomes the primary goal of therapy.
7. Lifestyle therapies for ASCVD risk reduction generally include interventions aimed at (1) dietary modifications (2) reducing total energy intake
to lower body weight and adiposity for those who are overweight or obese; (3) exercise (4) improving risk factors associated with the metabolic
syndrome (adiposity, dyslipidemia, high blood pressure, and elevated plasma glucose); and (5) ceasing tobacco use.
Verified By: 185848

Dr. Aravind P
MD Pathology


Page 11 Of 12
TEST REPORT
Bed
:
Biochemistry
LIVER FUNCTION TEST

BILIRUBIN TOTAL 0.40 mg/dl 0.1 - 1.2 Serum
Method:Diazo
BILIRUBIN DIRECT 0.20 mg/dl 0.0 - 0.3 Serum

Method:Diazo
BILIRUBIN INDIRECT 0.20 mg/dl 0.1 - 1.0 Serum
TOTAL PROTEIN 7.6 g/dL 6.4 - 8.3 Serum

Method:Biuret
ALBUMIN 4.6 g/dL 3.5 - 5.2 Serum

Method:BCG
GLOBULIN 3.0 g/dL 2.3-3.5 Serum

Method:Calculated
A/G RATIO 1.53 1-2 Serum

Method:Calculated
SGOT(AST) 28.0 U/L 5 - 40 Serum

Method:IFCC
SGPT (ALT) 62.0 U/L 5 - 41 Serum

Method:IFCC
GGT 50.0 U/L 3-40 Serum

Method:IFCC
ALKALINE PHOSPHATASE 55.0 U/L 40 - 130 Serum

Method:IFCC-PNPP With AMP Buffer
Total Bilirubin in Neonates

Age Premature (mg/dl) Mature (mg/dl)
0-1 day 1.0-8.0 2.0-6.0
1-2 days 6.0-12.0 6.0-10.0
3-5 days 10.0-14.0 4.0-8.0
*Teitz 5th ed
ALP in paediatric age group

Reference range IU/L
0-1 yr 150-350
1-16 yr 30-300
*Wallach 10th ed
Comments:
These are a panel of tests that help determine health of the liver by measuring the levels of proteins, liver enzymes and bilirubin in the blood. It
helps the clinician in differentiating between pre-hepatic, hepatic and post -hepatic causes of some conditions exhibiting jaundice as a symptom.
It is recommended in the following conditions:
1. To check for damage from liver infections (Hepatitis B, C etc)
2. To monitor the side effects of certain hepatotoxic drugs
3. To monitor effectiveness of treatment for liver diseases
4. If symptoms of liver or gall bladder conditions are seen (like jaundice, itchiness etc)
5. For certain medical conditions like diabetes, high triglycerides, anaemia etc

Page 12 Of 12
6. In liver damage caused by heavy alcohol consumption.
Verified By: 185848

Dr. Aravind P
MD Pathology


Lab Report

Uploaded by

Copyright:

Available Formats

You might also like

Lab Report

Uploaded by

Document Information

Original Description:

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Lab Report

Uploaded by

Copyright:

Available Formats

TEST REPORT

Lab. Id : P1508068 Hosp. UHID : Reg. Date : 05-Sep-2023 / 13:59 PM

KIDNEY FUNCTION TEST

CREATININE 0.90 mg/dl 0.8 - 1.44 Serum

URIC ACID 6.9 mg/dl 3.4 - 7.0 Serum

TOTAL PROTEIN 7.6 g/dL 6.4 - 8.3 Serum

ALBUMIN 4.6 g/dL 3.5 - 5.2 Serum

GLOBULIN 3.0 g/dL 2.3-3.5 Serum

A/G RATIO 1.53 1-2 Serum

ALKALINE PHOSPHATASE 55.0 U/L 40 - 130 Serum

CALCIUM 9.1 mg/dl 8.6 - 10.2 Serum

PHOSPHORUS 3.4 mg/dl 2.5-4.5 Serum

SODIUM 143.0 mmol/l 137-145 Serum

POTASSIUM 4.2 mmol/l 3.5-5.3 Serum

CHLORIDE 105.0 mmol/l 98-107 Serum

Verified By: 185848

Aster Clinical Lab Mangalore,Plot no 9, Building no 3E-16-1370/2, R sy no.97/2A, T Sy no 158/2A,kadri

--- End Of Report ---

Aster Clinical Lab Mangalore,Plot no 9, Building no 3E-16-1370/2, R sy no.97/2A, T Sy no 158/2A,kadri

COMPLETE BLOOD COUNT

RBC Count 5.50 mil/cmm 3.8-4.8 K2EDTA

PCV 47.9 % 36.0-46.0 K2EDTA

MCV 87.2 fl 76.0-96.0 K2EDTA

MCH 29.3 pg 27.0-32.0 K2EDTA

MCHC 33.6 g/dL 30.0-35.0 K2EDTA

RDW - CV 13.4 % 11 - 15 K2EDTA

Absolute Neutrophils 4628.8 /cmm 1500-8000 K2EDTA

Absolute Lymphocytes 3071.2 /cmm 1000-4500 K2EDTA

Aster Clinical Lab Mangalore,Plot no 9, Building no 3E-16-1370/2, R sy no.97/2A, T Sy no 158/2A,kadri

Absolute Monocytes 871.2 /cmm 0-800 K2EDTA

Absolute Eosinophils 149.6 /cmm 0-600 K2EDTA

Absolute Basophils 79.2 /cmm 0-200 K2EDTA

Verified By: 185848

Aster Clinical Lab Mangalore,Plot no 9, Building no 3E-16-1370/2, R sy no.97/2A, T Sy no 158/2A,kadri

--- End Of Report ---

Aster Clinical Lab Mangalore,Plot no 9, Building no 3E-16-1370/2, R sy no.97/2A, T Sy no 158/2A,kadri

GLUCOSE, FASTING (F) 111.0 mg/dl Non-Diabetic: < 100 Fluoride

Remarks: Sample was not collected in fasting state.

High levels are seen in:

Low levels are seen in:

Verified By: 185848

Aster Clinical Lab Mangalore,Plot no 9, Building no 3E-16-1370/2, R sy no.97/2A, T Sy no 158/2A,kadri

--- End Of Report ---

Aster Clinical Lab Mangalore,Plot no 9, Building no 3E-16-1370/2, R sy no.97/2A, T Sy no 158/2A,kadri

URINE ROUTINE EXAMINATION

pH-Urine 6.5 4.5 - 8.0 Spot urine

Specific Gravity Urine 1.010 1.016-1.022 Spot urine

Transparency Clear Clear Spot urine

Volume (ml) 15 ml Spot urine

Glucose Negative Negative Spot urine

Ketones Absent Absent Spot urine

Blood Absent Absent Spot urine

Bilirubin Absent Absent Spot urine

Urobilinogen Normal Normal Spot urine

Nitrite Absent Absent Spot urine

Casts Absent Absent Spot urine

Crystals Absent Absent Spot urine

Aster Clinical Lab Mangalore,Plot no 9, Building no 3E-16-1370/2, R sy no.97/2A, T Sy no 158/2A,kadri